| Autor: |
Peter J McCluskey, Thomas Hong, Andrew A Chang, John Grigg, Geoffrey K Broadhead, Timothy E Schlub, Eugenia Chu |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
BMJ Open Ophthalmology, Vol 9, Iss 1 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2397-3269 |
| DOI: |
10.1136/bmjophth-2023-001399 |
| Popis: |
Objective To assess the long-term efficacy and safety of oral saffron, a natural antioxidant, in treating mild/moderate age-related macular degeneration (AMD).Methods and analysis Open-label, extension trial of 93 adults (>50 years) with mild/moderate AMD and vision >20/70 Snellen equivalent in at least 1 eye. Exclusion criteria included confounding visual lesions or significant gastrointestinal disease impairing absorption.Participants were given oral saffron supplementation (20 mg/day) for 12 months. Those already consuming Age-Related Eye Diseases Study (AREDS) supplements or equivalent maintained these.Primary outcomes included changes in multifocal electroretinogram (mfERG) response density and latency, and changes in best-corrected visual acuity (BCVA). Secondary outcomes included safety outcomes, changes in mfERG and BCVA among participants on AREDS supplements and changes in microperimetry.Results At 12 months, mean mfERG response density was significantly higher in rings 1, 2 and overall (p0.05). Mean mfERG latency was not significantly different in any of rings 1–6 or overall (p>0.05 for all), again with no difference between those taking AREDS supplements or not (p>0.05). Mean BCVA was 1.6 letters worse (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
